QbD Group
    White Paper

    Organic and mutagenic impurities in pharma

    Ensure pharmaceutical quality and safety by controlling organic and mutagenic impurities. Download this whitepaper to learn more.

    October 9, 2024

    About this white paper

    Key topics covered in this resource

    The pursuit of high-quality active substances remains paramount in the pharmaceutical industry. A critical factor in achieving this goal is meticulous control of impurity content. Evaluating impurities in pharmaceuticals is essential to guarantee both their safety and efficacy.  These unintended molecules arise during synthesis, storage, or formulation, and some may harbor potential toxicity.

    Share this article

    QbD Group

    Need expert guidance?

    Ready to accelerate your life sciences project? Talk to our experts.

    Get expert guidance →